About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Allogeneic Hematopoietic Stem Cell Transplantation | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNPhase 2NCT00750126

Allogeneic Hematopoietic Stem Cell Transplantation

To assess the engraftment of hematopoietic stem cells following reduced-intensity conditioning in children presenting with solid tumors or hematological malignancy by evaluating post-transplantation c...

Lead sponsor: University Hospital, Clermont-Ferrand•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Lacarin Patrick

CONTACT

04.73.75.11.95 placarin@chu-clermontferrand.fr

Sponsors

Lead Sponsor

University Hospital, Clermont-Ferrand

Primary criterion * Hematological reconstitution and chimerism post-transplantation Secondary criteria * Adverse effects, graft-related mortality at D90 and at 12 months, incidence and severity of acute and/or chronic GVH reactions * Analysis of variations in post-transplantation immunological function profiles * Median duration of response in therapy-responsive patients and median duration of stability in stabilized patients

Age

0 - 20 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients aged less than 20 years old
•Lansky score \> 60%
•Life expectancy greater than 2 months
•Diagnoses:
•3- Solid tumor or hematological malignancy remaining unresponsive to the reference strategies according to French best practices in pediatrics.
•4- Malignancies for which allografting is the recognized indication but is contraindicated with myeloablative conditioning.
•Usual criteria for allogeneic grafting (pre-graft profile)
•Having a HLA-identical sibling donor for HLA-A, HLA-B and HLA-DR antigens or a HLA mismatch on only one antigen, or having a 10/10 pheno-identical donor, or compatible cord blood.
•Signed informed consent

Exclusion Criteria

•Patient presenting rapidly-progressive malignancy
•In cases where the potential donor is related, sibling presenting contraindication against hematopoietic stem cell donation
•Unable to sufficiently understand the treatment and its consequences, even after explanation

Related studies

RECRUITINGPhase 1/2

A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

NCT07060989 · Advanced Solid Tumors

RECRUITINGPhase 1

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

NCT06659341 · Advanced Solid Tumors Harboring KRAS G12C Mutation

RECRUITINGPhase 1/2

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

NCT05533697 · Advanced Solid Tumors

RECRUITINGPhase 1

A Study of PHST001 in Advanced Solid Tumors

NCT06840886 · Advanced Solid Tumors, Ovarian Cancer, and more

RECRUITINGPhase 1/2

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 19, 2011Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE2

Enrollment30

Start dateApr 2007

Last updatedJan 19, 2011

Condition

Solid Tumors Hematologic Neoplasms

Locations shown

Paillard Catherine

Clermont-Ferrand

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 19, 2011Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions